Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
152
-
Total 13F shares, excl. options
-
55.8M
-
Shares change
-
+1.65M
-
Total reported value, excl. options
-
$771M
-
Value change
-
+$8.67M
-
Put/Call ratio
-
0.85
-
Number of buys
-
65
-
Number of sells
-
-73
-
Price
-
$13.82
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2022
183 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2022.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 152 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.8M shares
of 105M outstanding shares and own 53.3% of the company stock.
Largest 10 shareholders include JPMORGAN CHASE & CO (6.69M shares), BlackRock Inc. (5.68M shares), Capital World Investors (4.59M shares), Palo Alto Investors LP (4.41M shares), VANGUARD GROUP INC (3.7M shares), Polar Capital Holdings Plc (3.12M shares), FRANKLIN RESOURCES INC (2.37M shares), STATE STREET CORP (1.78M shares), JENNISON ASSOCIATES LLC (1.76M shares), and BAMCO INC /NY/ (1.68M shares).
This table shows the top 152 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.